Targeting SRC-3 in immune cells as immunomodulatory therapeutics for treatment of cancer

The present disclosure relates to methods and compositions related to cancer treatment, including targeting SRC-3 in immune cells, including T cells, such as T regulatory cells. In particular, targeting SRC-3 in T regulatory cells is effective for eradicating tumors in mammals. In particular cases, T regulatory cells are subjected to ex vivo CRISPR to produce cells suitable for adoptive cell transfer. In some cases, one or more agents targeting SRC-3 are also administered to the individual and/or exposed to the cells prior to administration. 本公开涉及与癌症治疗相关的方法和组合物，包括靶向免疫细胞(包括T细胞，例如T调节细胞)中的SRC-3。特别是靶向T调节细胞中的SRC-3对于根除哺乳动物中的肿瘤是有效的。在特定情况下，对T调节细胞进行离体CRISPR，以产生适合过继性细胞转移的细胞。在一些情况下，将一种或多种靶向SRC-3的试剂也施用给个体和/或在施用前暴露于细胞。